Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Xoma and Nabi Garner NIH Support
September 15, 2008
| A version of this story appeared in
Volume 86, Issue 37
NIH's National Institute of Allergy & Infectious Diseases has awarded the antibody company Xoma a $65 million contract to develop botulism poisoning treatment drugs for the government's Strategic National Stockpile. The contract is the third awarded to Xoma by NIAID, bringing total funding to $100 million. Xoma intends to initiate human safety and animal efficacy studies of its first candidate in 2009. Meanwhile, NIAID and Nabi Biopharmaceuticals will conduct preclinical toxicology evaluations of two of Nabi's PentaStaph antigen vaccine candidates for the prevention and treatment of Staphylococcus aureus infections in community and hospital settings.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter